Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14422030 | 0.84 | GBA1 (0.48) | GBA1GNAO1CHRM5ADRA2CACHE | |
| SCHEMBL22907460 | 0.83 | GBA1 (0.41) | GBA1GNAO1CHRM5ADRA2CACHE | |
| SCHEMBL16303417 | 0.83 | GBA1 (0.50) | GBA1GNAO1CHRM5ADRA2CACHE | |
| SCHEMBL2570307 | 0.82 | GBA1 (0.47) | GBA1GNAO1CHRM5ADRA2CACHE | |
| Hydrochloric Acid SCHEMBL5573130 | 0.82 | GBA1 (0.47) | GBA1GNAO1CHRM5ADRA2CACHE | |
| SCHEMBL12717723 | 0.82 | GNAO1 (0.47) | GBA1GNAO1CHRM5ADRA2CACHE | |
| SCHEMBL3580056 | 0.82 | NCF1 (0.43) | GBA1GNAO1CHRM5ADRA2CACHE | |
| SCHEMBL13801431 | 0.81 | GNAI3 (0.49) | GBA1GNAO1CHRM5ADRA2CACHE | |
| SCHEMBL3062251 | 0.80 | CHRM5 (0.56) | GBA1GNAO1CHRM5ADRA2CACHE | |
| SCHEMBL528918 | 0.80 | CHRM5 (0.62) | GBA1GNAO1CHRM5ADRA2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| EP-1789410-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029906-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | DRD2, DRD4, PNMT | GBA1 839/4885GNAO1 3472/4885CHRM5 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.